Biomedical Engineering Reference
In-Depth Information
Table 6.3
Clinical outcome of high-risk patients undergoing cardiac surgery
with different CPB protocols
Coating and
Leukofi lter
Filter
Control
P
Duration of CPB (min)
118.5
±
7
124.4
±
7
133.2
±
8 S
Duration of x-clamp (min)
a
89.4
±
4
91.3
±
4
104.2
±
4 S
Respiratory support time,
t-intub (h)
11.2
±
2*
12.7
±
1*
18.9
±
2.5
<
0.05
Post-op hemorrhage (mL)
570
±
50*
890
±
50
835
±
50
<
0.05
Arrhythmia (
n
)
AF:3*
AF:2*
AF:10
<
0.05
Blood transfusion (units)
2.7
±
0.5*
4.9
±
0.5
5.3
±
0.5
<
0.05
Blood products (units)
2.6
±
0.5*
5.9
±
0.5
5.6
±
0.5
<
0.05
Inotropic support (
n
)
9*
11
16
<
0.05
IABP (
n
)
b
2*
5
8
<
0.05
Neurologic complications (
n
)
1
2
5
S
Renal complications (
n
)
0
1
4
NS
ICU stay (days)
c
2.9
±
0.1*
4.2
±
0.1
5.9
±
0.1
<
0.05
Postop NYHA classifi cation
d
2.9
±
0.1
2.7
±
0.1
3.2
±
0.1
NS
Postoperative EF (%)
40.2
±
8
42.1
±
8
36.4
±
7
S
Hospital stay (days)
7.9
±
1*
9.8
±
1
12.4
±
1
<
0.05
Mortality rate (%)
2 (8%)*
3(12%)
5 (20%)
<
0.05
a
x-clamp, aortic cross-clamp.
b
IABP, intra-aortic ballon pump.
c
ICU, intensive care unit.
d
NYHA, New York Heart Association.
*Signifi cant difference with respect to control.
1
0003
80 kV ×500
10
μ
m
6.7
Scanning electron microscopy image of leukocyte fi lter fi ber with
captured leukocytes.
Search WWH ::
Custom Search